Episode 69: The Widespread Effects of DMT Waste in Multiple Sclerosis
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin T. Okuda, MD, and Karin Cook. [LISTEN TIME: 55 minutes]
Darin T. Okuda, MD
Karin Cook
Episode 69 of the NeurologyLive Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 69, "The Widespread Effects of DMT Waste in Multiple Sclerosis," features an exclusive interview with Darin T. Okuda, MD, professor of neurology and director of Neuroinnovation and the Multiple Sclerosis & Neuroimmunology Imaging Program at The University of Texas Southwestern Medical Center at Dallas; and Karin Cook, senior vice president of medical strategy and clinical ethnographer, Heartbeat Medical Communications. The pair spoke about their research into the wasted costs associated with disease-modifying therapies (DMTs) for patients with multiple sclerosis,1 what they've observed at their center, the wide-reaching impact of this waste on the healthcare continuum, and the future solutions that are being worked on for this problem.
Click here for more coverage of this story: Multiple Sclerosis DMT Waste Is Staggering, New Study Shows
This episode is brought to you by Medical World News. Check out new episodes of a variety of shows, airing every single day, only on medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Zonisamide Oral Suspension FDA-Approved for Partial Seizures in Epilepsy
- FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy
- FDA Clears Rapid Hyperdensity Tool for Inclusion in RapidAI Platform for Neurovascular Conditions
- ALS Therapy Tofersen Has NDA Accepted by FDA, Granted Priority Review
EPISODE BREAKDOWN
1:45 – Background on the study conducted by Okuda et al.
4:05 – Perspective on the cost driven by DMT waste
6:30 – Current landscape of prescriptions and adherence in MS
8:35 – Disparities in MS treatment adherence
11:00 – The link to the physician-patient relationship
16:40 – The process of choosing a DMT and shared decision-making
23:00 – Neurology News Minute
25:45 – Finding solutions to the DMT waste problem
33:40 – The role of the individual neurologist and patient
38:30 – Access to specialist care and resources
42:40 – Building trust with patients and general medical mistrust
47:00 – Next steps and closing thoughts
Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!
